Aug 29, 2019
Starpharma sees positive results in ovarian cancer treatment

Online investor news outlet Finance News Network reported Starpharma’s positive results for its novel HER-2 targeted DEP® conjugate (ADC) which outperformed the leading HER-2 ADC, Kadcyla®, in a human ovarian cancer model. |
To watch the full news video, click here.
This contains certain forward-looking statements.